Report ID : 10151875 |
Published Date : 21 Oct 2022 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Market Overview:
Global Healthcare Nanotechnology Industry Market Research 2022-2030
"In 2021, the healthcare nanotechnology (nanomedicine) market is estimated to be valued at USD ~240 billion and is expected to expand at a CAGR of ~12% during the forecast period of 2022-2030. Opportunities to develop new strategies in the prevention, diagnosis and treatment of COVID-19 and other viral infections.
The management of COVID-19 is carried out with the development of nanomaterials, such as disinfectants for treatment and vaccine development, personal protective equipment, diagnostic systems, and nanocarrier systems. According to a research article published by Estefania VR Campos et al. in the "Journal of Nanobiotechnology in 2020, gold nanoparticles are functionalized with probes modified with sulfhydryl groups on the surface, which can hybridize with the target and prevent the aggregation of nanoparticles.
Therefore, the color will change. This solution can be easily applied to the diagnosis of COVID-19. The growth of the healthcare nanotechnology (nanomedicine) market is currently being driven by various factors, such as the increasing prevalence of cancer, genetic and cardiovascular diseases, the continuous advancement of nano-level diagnostic procedures and the increasing preference for personalized medicine And to provide solutions for various life-threatening diseases, such as cancer, Parkinsons disease, Alzheimer;s disease, diabetes, orthopedic diseases, and diseases related to the blood, lung and cardiovascular system.
According to data from Alzheimer's Disease International, in 2020, approximately 50 million people worldwide will suffer from dementia. This number is expected to double every 20 years, reaching 82 million in 2030 and 152 million in 2050. Therefore, the high burden of dementia is expected to increase the demand for effective nanomedicine-based treatments, which is expected to drive market growth. In addition, market participants frequently participate in product launches to increase their market share. For example, in October 2020, Medtronic PLC launched the new Adaptix Interbody System, a titanium spinal implant that uses Titan nanoLOCK surface technology for navigation. However, compared with traditional peers, strict regulatory issues and the high cost of nanoparticle-assisted medicine are hindering market growth.
Reporting scope:
According to the scope of the report, the medical nanotechnology (nanomedicine) market includes existing drugs or new drugs or nano-preparation products of nanomaterials. The market is broken down by application (drug delivery, biomaterials, active implants, imaging and tissue regeneration), disease (cardiovascular disease, tumor disease, neurological disease, orthopedic disease, infectious disease, and other diseases) and geographic (Northern United States) Minute. , Europe, Asia Pacific, Middle East and Africa, and South America). The report provides the market size and value forecasts (in millions of US dollars) for the aforementioned market segments.
Main market trends:
The neurological disease segment is expected to show better growth during the forecast period. Nanomedicine is a promising cancer treatment model. This evolving field of medical research can be used to discover better tailored treatments for various diseases, including cancer. Globally, the prevalence of cancer is increasing. For example, according to Globocan, the global cancer burden will increase to 19.3 million cases in 2020, and 10 million people will die of cancer in 2020. In the field of oncology, nanomedicine provides a promising transformation of existing treatment and cancer diagnosis methods. Significant progress has been made in the application of nanotechnology-based cancer diagnosis and treatment methods, and many new advances are currently in the pipeline.
According to a research article published by the American Chemical Society, a total of 75 anticancer nano-drugs are under development. As of 2019, cancer is undergoing clinical research. Among the ongoing and completed clinical trials, 91 (48) are in phase 1, 78 (59) are in phase 2, and 21 (11) are in phase 3. The success rate of phase 1 trials has been high (about 94%). In April 2019, Hensify (NBTXR3), an aqueous suspension of crystalline hafnium oxide (HfO2) from Nanobiotix, a clinical-stage nanomedicine company, received CE approval.
Nanoparticles designed to be injected directly into the tumor before the patients first standard radiotherapy. According to a research article by Ye Zhang et al., published in the 2019 Journal of Hematology and Oncology, researchers at Memorial Sloan Kettering Cancer Center and Cornell University developed hybrid silica nanoparticles (point s C) PET imaging for patients with metastatic melanoma or malignant brain tumors. These nanoparticles bind to the 124 I-labeled cyclic-[Arg-Gly-Asp-Tyr] (cRGDY) peptide, which can selectively bind integrins and can be used to detect tumor cells.
North America is expected to have the largest market share:
The main factors for growth are technological advancements and related applications in early disease diagnosis, preventive intervention, and chronic and acute disease prevention. This is expected to drive the growth of the North American market. The Heart Association research reports that one in seven deaths in the United States is due to cardiovascular disease (CVD). In 2018, coronary heart disease was the leading cause of cardiovascular death in the United States, accounting for 43.8% of all cardiovascular deaths, followed by stroke (16.8%), heart failure (9.0%) and arterial hypertension (9.4%). %), arterial disease (3.1%) and other cardiovascular diseases (17.9%).
This may generate high demand for specific therapeutic nanocarriers, nanostructured scaffolds and tissue regeneration implants. In addition, the country is also carrying out a number of R&D activities in nanotechnology-based drugs and diagnostics, which can promote market growth . For example, in January 2020, researchers at Stanford University developed a nanoparticle-coated drug that limits the development of atherosclerosis in mice by reducing the accumulation of plaque in the arteries without harmful side effects.
Develop novel products and technologies to compete with existing products, while other companies are acquiring and cooperating with other trending companies in the market. In 2020, Nano-X Imaging and SPI Medical signed an agreement to distribute and introduce a new Nanox X-ray system in Mexico. Nanox ARC uses nanotechnology and semiconductors to replace cathode ray tubes in traditional machines. In addition, during the COVID-19 pandemic, nanomedicine was found to play a key role in vaccine development.
Scientists and market participants in the region are increasing experimental research to find suitable and promising therapies that may be effective against the highly infectious COVID-19 virus. In October 2020, the Canadian government announced that it would provide Precision NanoSystems with US$18.2 million in funding for the development of an RNA vaccine for COVID-19. This investment will support the development of cost-effective COVID-19 vaccines using nanomedicine and lipid-based drug delivery systems.
Competitive landscape:
Major market players focus on technological advancements and improvements in drug bioavailability and delivery. The lucrative growth opportunities brought about by the COVID-19 pandemic are expected to drive new players into the market. Some of the major players in the market are Sanofi, Pfizer, New Foundation, Luminex, and Taiwan Liposome Co., Ltd. In addition, several companies are working to launch nanotechnology-based drugs and diagnostic tools.
For example, in August 2020, Promimic partner Innovasis Inc. received US FDA approval and released 3D printed implants for spinal fusion surgery. In addition, these implants use Promimics HAnano surface technology, a bioactive nano-treatment used on the surface of implanted devices to increase molecular anchoring of medical implants.
Major Players
Sanofi SA
Pfizer Inc.
Taiwan Liposome Company Ltd
Johnson & Johnson
Bristol-Myers Squibb Company
Update:
November 2020-BioNtech and Pfizer announced the results of two nanoparticle-based vaccines. In addition, in May 2020, Epidemic Prevention Innovation (CEPI) announced that it will spend $384 million to develop Novavax, a nanoparticle-based COVID-19 vaccine. , Developed a gel that uses nanoparticles to destroy brain cancer patients after surgery, especially the remaining cancer cells in glioblastoma."
Related Reports
Proof of Quality & Reliability
